Gathering the record
Relay is organizing the evidence and source boundaries.
GLP-1 receptor agonist
Liraglutide is a once-daily GLP-1 receptor agonist used in FDA-approved products for chronic weight management and type 2 diabetes. It has a long human evidence record, including cardiovascular outcomes, but the named products and their labeled doses are not interchangeable.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Liraglutide is a medicine that imitates one natural hormone signal involved in appetite, digestion, and blood-sugar regulation. Approved products include Saxenda and Victoza.
Its long human record lets researchers study weight, diabetes, cardiovascular risk, pediatric populations, and several narrower metabolic questions. The breadth also shows why one ingredient can have product- and population-specific conclusions.
Large randomized trials support approved weight-management and diabetes uses, including a cardiovascular benefit in adults with type 2 diabetes at high cardiovascular risk. Smaller studies have explored sleep apnea, prediabetes, and fatty-liver disease without creating separate U.S. indications.
Durability after treatment ends, rare harms, comparisons with newer weekly medicines, and whether smaller research signals become approved uses remain incomplete. The approved ready-to-use products do not validate independent powder vials.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A published Phase 3 trial evaluated a specific liraglutide product regimen in adults with obesity or overweight plus a related condition who did not have type 2 diabetes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
More than a decade of controlled trials and approved-product experience spans diabetes, weight, cardiovascular outcomes, and pediatric populations.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Large randomized trials support defined product-specific uses; smaller sleep, liver, and prediabetes studies do not create additional approved indications.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trial included lifestyle support and a defined product, population, and escalation procedure. Saxenda and Victoza evidence is product specific and does not establish reconstitution or stability for powder vials. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple randomized Phase 3 trials plus the 9,340-participant LEADER cardiovascular outcomes trial support approved product-specific weight, diabetes, pediatric, and cardiovascular findings.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
How long-term outcomes compare with newer weekly incretin therapies, how benefits persist after discontinuation, and whether smaller signals in sleep apnea, prediabetes, or fatty-liver disease translate into approved uses.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Current U.S. labels cover chronic weight management under Saxenda and glycemic control plus defined cardiovascular-risk reduction under Victoza. The product contexts are not interchangeable.
SCALE reported greater average weight loss and more participants reaching weight-reduction thresholds than placebo.
The Victoza label and ELLIPSE trial support glycemic-control evidence beginning at age 10 in defined type 2 diabetes populations.
The primary outcome occurred in 13.0% with liraglutide and 14.9% with placebo over a median 3.8 years.
Controlled studies reported signals in each area, with especially important limitations in the high-withdrawal prediabetes extension and the small LEAN liver trial.
STEP 8 reported mean changes of -15.8% with weekly semaglutide and -6.4% with daily liraglutide at 68 weeks.
Saxenda and Victoza are both daily injections, but their labeled dose ranges, purposes, and patient instructions differ.
The current labels describe clear, colorless 6 mg/mL solution in prefilled single-patient-use pens.
The labels include a boxed thyroid C-cell-tumor warning, MTC/MEN2 contraindication, and warnings involving pancreatitis, gallbladder disease, severe gastrointestinal reactions, volume depletion, hypoglycemia in relevant combinations, and aspiration around anesthesia or deep sedation.
Mechanisms
Liraglutide is an acylated GLP-1 analog with GLP-1-receptor agonist activity and an approximately 13-hour half-life that supports once-daily administration. Its evidence base includes randomized weight-management trials in adults and adolescents, glycemic-control trials in adults and youth, and the 9,340-participant LEADER cardiovascular outcomes trial. Smaller or narrower trials have also evaluated prediabetes progression, obstructive sleep apnea, visceral adiposity, and NASH.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized 68-week trial; active treatments were open-label and each had a matched blinded placebo
Adults with obesity or overweight plus comorbidity, without diabetes
Mean weight change was -15.8% with semaglutide and -6.4% with liraglutide. Gastrointestinal adverse events were reported by 84.1% and 82.7%, respectively.
Study administration: Once-weekly subcutaneous semaglutide 2.4 mg, once-daily subcutaneous liraglutide 3.0 mg, or matched placebo, with lifestyle counseling
Limitations: The active-treatment comparison was open-label, used specific obesity products and escalation protocols, and does not compare diabetes, cardiovascular, kidney, or liver outcomes.
Randomized, double-blind, placebo-controlled trial
Adolescents age 12 to under 18 with obesity and an inadequate response to lifestyle therapy
Liraglutide improved the BMI standard-deviation score versus placebo. At least 5% BMI reduction occurred in an estimated 43.3% versus 18.7%, and at least 10% in 26.1% versus 8.1%.
Study administration: Once-daily subcutaneous liraglutide up to 3.0 mg or placebo, with lifestyle therapy
Limitations: The population was adolescents with obesity after inadequate lifestyle response. Gastrointestinal events and treatment discontinuation were more frequent with liraglutide.
Randomized, double-blind, placebo-controlled trial with extension
Children and adolescents age 10 to under 17 with type 2 diabetes receiving metformin, with or without basal insulin
At week 26, mean HbA1c decreased 0.64 percentage points with liraglutide and increased 0.42 points with placebo, an estimated difference of -1.06 points.
Study administration: Once-daily subcutaneous liraglutide up to 1.8 mg or placebo, added to metformin with or without basal insulin
Limitations: This was a pediatric type 2 diabetes trial, not a pediatric weight-management trial, and all participants received metformin.
Randomized, double-blind, placebo-controlled extension
Adults with obesity or overweight plus comorbidity and prediabetes
While on treatment, diabetes was diagnosed in 2% with liraglutide and 6% with placebo; the hazard ratio for diabetes onset was 0.21. Weight change at week 160 was -6.1% versus -1.9%.
Study administration: Once-daily subcutaneous liraglutide 3.0 mg or placebo, with reduced-calorie diet and physical activity
Limitations: Only half of participants completed 160 weeks, and people who withdrew were not followed after discontinuation. Prediabetes prevention is not a separately labeled U.S. indication.
Randomized, double-blind, placebo-controlled, event-driven trial
Adults with type 2 diabetes and high cardiovascular risk
The primary cardiovascular outcome occurred in 13.0% with liraglutide and 14.9% with placebo (hazard ratio 0.87). Cardiovascular death occurred in 4.7% versus 6.0%.
Study administration: Once-daily subcutaneous liraglutide up to 1.8 mg or placebo, added to usual care
Limitations: The cardiovascular result applies to a high-risk type 2 diabetes population and a diabetes-product regimen; it is not evidence for cardiovascular prevention in every population.
Randomized, double-blind, placebo-controlled trial
Adults with obesity and moderate or severe obstructive sleep apnea who were unable or unwilling to use CPAP
The apnea-hypopnea index decreased by 12.2 events per hour with liraglutide and 6.1 with placebo; weight decreased 5.7% versus 1.6%.
Study administration: Once-daily subcutaneous liraglutide 3.0 mg or placebo, with diet and physical-activity counseling
Limitations: The trial did not compare liraglutide with CPAP, and current U.S. liraglutide labels do not include an obstructive-sleep-apnea indication.
Multicenter, randomized, double-blind, placebo-controlled trial
Adults with overweight and biopsy-confirmed nonalcoholic steatohepatitis, with or without type 2 diabetes
NASH resolution without worsening fibrosis occurred in 39% of evaluable liraglutide participants and 9% of placebo participants.
Study administration: Once-daily subcutaneous liraglutide 1.8 mg or placebo
Limitations: LEAN was a small Phase 2 study with 45 end-of-treatment biopsies. Current U.S. liraglutide labels do not include a MASH or NASH indication.
Randomized, double-blind, placebo-controlled trial
Adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes
Mean weight change was -8.4 kg with liraglutide and -2.8 kg with placebo. At least 5% weight reduction occurred in 63.2% versus 27.1%, and more than 10% in 33.1% versus 10.6%.
Study administration: Once-daily subcutaneous liraglutide 3.0 mg or placebo, with diet and physical-activity counseling
Limitations: The trial used a defined 3.0 mg product regimen plus lifestyle support and excluded type 2 diabetes. Group averages do not predict an individual result.
Safety snapshot
Current liraglutide labels include important contraindications, warnings, and common gastrointestinal adverse reactions.
Controlled human evidenceThis is a high-level safety summary, not a substitute for the complete current label or professional medical assessment.
Open sourceCurrent liraglutide labels include important contraindications, warnings, and common gastrointestinal adverse reactions.
Controlled human evidenceThe stated frequency is source-, product-, population-, route-, dose-, comparator-, and duration-specific; it is not a universal incidence estimate.
Open sourceLEADER demonstrated fewer major cardiovascular events with liraglutide in adults with type 2 diabetes and high cardiovascular risk.
Controlled human evidenceThe result applies to the studied high-risk diabetes population and does not establish cardiovascular benefit for every liraglutide use.
Open sourceWhile on treatment, diabetes was diagnosed in 2% with liraglutide and 6% with placebo; the hazard ratio for diabetes onset was 0.21. Weight change at week 160 was -6.1% versus -1.9%.
Controlled human evidenceStudy discontinuation describes what happened under a study protocol; it is not an emergency-action threshold.
Open sourceNo compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-01
2025-10-14
2022-01-11 · PMID 35015037 · NCT04074161 · DOI 10.1001/jama.2021.23619
2020-03-31 · PMID 32233338 · NCT02918279 · DOI 10.1056/NEJMoa1916038
2019-04-28 · PMID 31034184 · NCT01541215 · DOI 10.1056/NEJMoa1903822
2017-02-22 · PMID 28237263 · NCT01272219 · DOI 10.1016/S0140-6736(17)30069-7
2016-06-13 · PMID 27295427 · NCT01179048 · DOI 10.1056/NEJMoa1603827
2016-03-23 · PMID 27005405 · NCT01557166 · DOI 10.1038/ijo.2016.52
2015-11-20 · PMID 26608256 · NCT01237119 · DOI 10.1016/S0140-6736(15)00803-X
2015-07-02 · PMID 26132939 · NCT01272219 · DOI 10.1056/NEJMoa1411892